Lebrikizumab maintains clinically meaningful improvements in itch and skin lesions for up to five years in patients with moderate-to-severe atopic dermatitis, according to long-term data reported by The Dermatology Digest.

The findings address one of the central questions in atopic dermatitis management: whether biologic efficacy holds up over extended treatment periods. Lebrikizumab, a monoclonal antibody that inhibits interleukin-13, has already demonstrated efficacy in controlled induction and maintenance trials. The new long-term data extend that record across a five-year horizon, covering both pruritus and lesional outcomes.

Sustained itch relief matters clinically. Chronic pruritus drives sleep disruption, impaired quality of life, and treatment discontinuation in atopic dermatitis, and loss of itch control over time is a common reason patients cycle off therapy. The reported durability of lebrikizumab's effect on itch over five years suggests the IL-13 blockade mechanism continues to deliver where patients feel it most.

Lesional improvements persisted alongside the itch benefit, indicating that the drug's effect on objective skin disease — not just symptom control — remains stable with continued dosing.

For dermatologists, the data add to the growing long-term safety and efficacy record of IL-13–targeted therapy in atopic dermatitis, alongside the established IL-4/IL-13 inhibitor dupilumab. Durable response data increasingly factor into treatment selection, payer discussions, and shared decision-making with patients who face years — potentially decades — of disease management.

Longer-term datasets like this one will help clarify how lebrikizumab fits into chronic treatment algorithms as clinicians weigh persistence of response against dosing convenience, safety monitoring, and access considerations.